IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32253-9.html
   My bibliography  Save this article

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

Author

Listed:
  • Samah Hayek

    (Clalit Health Services)

  • Yatir Ben-shlomo

    (Clalit Health Services)

  • Noa Dagan

    (Clalit Health Services
    Ben Gurion University
    Harvard Medical School
    The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute)

  • Ben Y. Reis

    (The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute
    Boston Children’s Hospital
    Harvard Medical School)

  • Noam Barda

    (Ben Gurion University
    Harvard Medical School)

  • Eldad Kepten

    (Clalit Health Services)

  • Alina Roitman

    (Clalit Health Services)

  • Shachar Shapira

    (Israel Defense Forces Medical Corps
    Hebrew University)

  • Shlomit Yaron

    (Clalit Health Services)

  • Ran D. Balicer

    (Clalit Health Services
    The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute
    Ben Gurion University of the Negev)

  • Doron Netzer

    (Clalit Health Services)

  • Alon Peretz

    (Clalit Health Services)

Abstract

REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-19-related hospitalization, severe disease, and death. We compared patients infected with Delta variant and treated with REGEN-COV (n = 289) to those infected but not-treated with REGEN-COV (n = 1,296). Demographic and clinical characteristics were used to match patients and for further adjustment as part of the C0x model. Estimated treatment effectiveness was defined as one minus the hazard ratio. Treatment effectiveness of REGEN-COV was 56.4% (95% CI: 23.7–75.1%) in preventing COVID-19 hospitalization, 59.2% (95% CI: 19.9–79.2%) in preventing severe COVID-19, and 93.5% (95% CI: 52.1–99.1%) in preventing COVID-19 death in the 28 days after treatment. In conclusion, REGEN-COV was effective in reducing the risk of severe sequelae in high-risk COVID-19 patients.

Suggested Citation

  • Samah Hayek & Yatir Ben-shlomo & Noa Dagan & Ben Y. Reis & Noam Barda & Eldad Kepten & Alina Roitman & Shachar Shapira & Shlomit Yaron & Ran D. Balicer & Doron Netzer & Alon Peretz, 2022. "Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32253-9
    DOI: 10.1038/s41467-022-32253-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32253-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32253-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32253-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.